Qiagen (NYSE:QGEN) Issues Earnings Results

Qiagen (NYSE:QGEN) announced its quarterly earnings results on Wednesday. The company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.01, Zacks reports. Qiagen had a net margin of 4.73% and a return on equity of 13.43%.

Qiagen Trading Up 0.9 %

Shares of QGEN traded up $0.40 during midday trading on Wednesday, hitting $43.76. The stock had a trading volume of 1,533,236 shares, compared to its average volume of 1,163,455. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. The firm has a market cap of $9.71 billion, a P/E ratio of 109.09, a price-to-earnings-growth ratio of 3.10 and a beta of 0.36. Qiagen has a fifty-two week low of $40.15 and a fifty-two week high of $49.30. The business has a 50-day simple moving average of $43.78 and a two-hundred day simple moving average of $43.25.

Analyst Upgrades and Downgrades

Several research firms have recently commented on QGEN. Jefferies Financial Group restated a “buy” rating and set a $52.50 price target (up previously from $40.83) on shares of Qiagen in a research note on Tuesday, December 10th. HSBC lowered Qiagen from a “buy” rating to a “hold” rating and set a $47.64 target price on the stock. in a research note on Thursday, October 17th. Morgan Stanley restated an “equal weight” rating and issued a $46.67 target price (down from $48.61) on shares of Qiagen in a report on Monday, January 6th. Finally, Hsbc Global Res raised Qiagen to a “hold” rating in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $50.07.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.